Patterson Matthew R, Chief Executive Officer, subtracted 14,426 shares of Audentes Therapeutics, Inc. (BOLD) from its portfolio at the rate of $30.00 per share valuing $432,780 on Nov 08. The insider left behind 113,394 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $59.08, with a 2nd Resistance Point sitting at $59.22. Meanwhile, this company’s stock has a 1st Support Level at $58.72 and a 2nd Support Level at $58.50. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Audentes Therapeutics, Inc. (BOLD) was $58.93. Audentes Therapeutics, Inc. (BOLD) stock has gained $29.54, or 104.90%, in the past five days. In the last full month, these shares have gained $29.87, or 102.79%. In the past three months, this stock’s price has risen by $29.03, or 97.09%. This year-to-date, Audentes Therapeutics, Inc. (BOLD) shares have gained $37.61, or 176.41%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Audentes Therapeutics, Inc. (BOLD) stock, Hold % of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 50% of long-term indicators suggest that this stock is a “ Buy .”
With 45,783 K shares outstanding, this company currently has a market capitalization of $1,309,852K. Audentes Therapeutics, Inc. (BOLD) generates annual net income of -$128,820 K. This stock has generated a 1-Year Total Return of 134.87%, a 3-Year Total Return of 70.10%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Audentes Therapeutics, Inc. (BOLD) reported earnings of -$1.00 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$1.07 per share, representing a 0.07 difference and 6.54% surprise. In the previous quarter ending in 06/19, the reported earnings of -$1.01 represented a 0.07 difference from the consensus estimate calling for -$1.08 per share, which was a 6.48% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$1.01 per share. This estimate came from a total of 8 Wall Street Analysts. Of those market experts, the high estimate was -$0.89 and the low estimate was -$1.07. In the year-ago quarter, Audentes Therapeutics, Inc. (BOLD) generated per-share earnings of -$0.84. If the analysts are correct about the current quarter’s earnings, the growth will be -20.24%.
Turning our focus now to insider trading activity, there have been 1 purchases (14,426 shares in total) and 7 sale (28,410 shares in total) in the last 3 months. In the last 6 months, there have been 3 insider buys amounting to 64,426 shares and 18 insider sales amounting to 75,517 shares. In the past full year, 14 insider purchases were made (involving 318,925 shares) and 31 insider sell-offs equivalent to 170,075 shares.
Moving onto liquidity, Audentes Therapeutics, Inc. (BOLD) has a Current Ratio of 17.60, a Quick Ratio of 17.60 and a Cash Ratio of 17.37.